Elanco provided USDA license for Canine Parvovirus Monoclonal Antibody

Elanco announced the U.S. Department of Agriculture, or USDA, has provided a conditional license for the first Canine Parvovirus Monoclonal Antibody. This is the first and only approved therapeutic solution proven to treat canine parvovirus, one of the most contagious and deadly viruses a dog can contract with a 91% mortality rate if not treated with supportive care. The treatment is the first monoclonal antibody for Elanco.